Last reviewed · How we verify
Zyprexa IM
At a glance
| Generic name | Zyprexa IM |
|---|---|
| Sponsor | Impel Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department (PHASE3)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- IM Olanzapine Versus Haloperidol or Midazolam (PHASE4)
- Olanzapine Versus Midazolam for Agitation
- Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101 (PHASE1)
- Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis (PHASE2)
- Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward (PHASE4)
- Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zyprexa IM CI brief — competitive landscape report
- Zyprexa IM updates RSS · CI watch RSS
- Impel Pharmaceuticals portfolio CI